Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novogen's Promensil

This article was originally published in The Tan Sheet

Executive Summary

Five-year-old Australian firm officially launching product containing 40 mg red clover-derived phytoestrogen isoflavones, designed for menopausal symptoms, at health food stores nationwide beginning April 7. The product was introduced in the U.S. on QVC March 8; Leiner has the electronic marketing rights to Promensil. During the last three months of 1997, the product had sales of $1.3 mil. in Australia; it has been available in the U.S. on very limited basis from physicians and is the company's inaugural dietary supplement. Novogen will spend $5 mil. on advertising and promotion, including print ads in women's books, as well as public relations, health seminars, medical journal ads and point-of-sale materials, according to promotional literature to the trade. Lally McFarland Pantello, New York City, is handling the advertising and Ruder, Finn, New York City, the PR. Novogen showed the product to over 24,000 registered health food/supplement store retailers March 13-15 at Natural Products Expo West in Anaheim, Calif...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel